25 09, 2020

What is Minimal Residual Disease (MRD)?

By | September 25th, 2020|Categories: Early detection, Epigenomics, MRD, Next-generation sequencing|0 Comments

Many of my followers in the cancer space, especially the Hemes folks, will already understand what MRD is and why it’s important. But for those of you who don’t know I thought an explainer might be helpful. I took inspiration from Keiths COVID qPCR explainer and this […]

30 07, 2020

Happy 6th birthday $1000 genome…

By | July 30th, 2020|Categories: Epigenomics, Next-generation sequencing, Other stuff|3 Comments

When I wrote the post about the $1000 genome’s upcoming 5th birthday last Summer I was hoping the Moore’s Law genome graph would restart it’s downward trajectory. That has not happened according to todays look at their graphic. I’m beginning to wonder how long we’ll […]

23 06, 2020

Brain cancer testing without the invasive biopsy from @decarvalho_lab

By | June 23rd, 2020|Categories: Diagnostics Tech, Early detection, Epigenomics|0 Comments

Brain cancer is difficult to diagnose and stratify without an invasive biopsy. Daniel De Carvalho’s group have used their cfChIP-Seq technology to non-invasively diagnose and classify brain tumours, potentially removing the need for surgical tissue biopsies. The power of the assay comes from its use of […]

5 06, 2020

Avida Biomed: early cancer detection with methylation

By | June 5th, 2020|Categories: Diagnostics Tech, Early detection, Epigenomics, MRD|0 Comments

Avida Biomed are an early startup who have developed a novel targeted methylation sequencing technology: Point-n-Seq, for cancer early-detection. Point-n-Seq uses targeted methylation sequencing, which performs enrichment of target molecules directly from cfDNA before bisulfite conversion and amplification. Target panels are small 1-1000 markers. The […]

Load More Posts